Skip to main content
Premium Trial:

Request an Annual Quote

Tempus to Provide NGS Cancer Tests to US Department of Veterans Affairs

NEW YORK — Tempus said on Friday that it has struck a multiyear deal to provide its next-generation sequencing-based cancer tests to the US Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP). 

Under the terms of the deal, NPOP healthcare providers at the VA's 171 medical centers can access the tests including Tempus' solid tumor/normal and liquid biopsy assays. In the event of insufficient tumor tissue, Chicago-based Tempus said it offers a conversion option to a blood-based liquid biopsy test. 

Financial and other terms were not disclosed. 

"Our AI-enabled tests combine high-quality and comprehensive genomic data with clinical data for each patient being sequenced, which allows physicians to make truly personalized decisions as they seek the optimal therapy for their patients," Tempus Founder and CEO Eric Lefkofsky said in a statement. "We look forward to supporting the VA as they expand access to precision medicine solutions in oncology care." 

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.